British Dragon Letrobol contains Letrozole in oral tablet form, formulated at 2.5 mg per tablet. As a low-dose compound, Letrozole requires precise dosing to ensure consistent performance, making independent lab testing especially important.
Below is the latest available lab test confirming the potency of Letrobol 2.5 mg, conducted by a trusted third-party laboratory.
Latest Lab Result (2026)
Janoshik Lab Report – 2026-03-23
- Product: Letrobol
- Active Substance: Letrozole
- Manufacturer: British Dragon
- Labeled Dosage: 2.5 mg/tablet
- Result: 2.52 mg/tablet
- Laboratory: Janoshik
This lab test shows a measured content of 2.52 mg per tablet, almost perfectly matching the labeled 2.5 mg dosage. This result indicates highly accurate formulation with minimal deviation.
Potency Analysis
- Labeled dosage: 2.5 mg
- Measured dosage: 2.52 mg
- Deviation: ~+0.8%
- Laboratory: Janoshik
The extremely small deviation demonstrates a high level of manufacturing precision, particularly important for low-dose tablet formulations.
About Letrobol (Letrozole)
Letrozole is an aromatase inhibitor commonly used in oral tablet form, where precise dosing is essential due to its low milligram strength. Even minor variations can be significant, making accurate formulation and verification critical.
Independent lab testing provides confirmation that each tablet delivers a dosage very close to its labeled amount.
Conclusion
The available lab test for British Dragon Letrobol 2.5 mg shows a measured dosage of 2.52 mg per tablet, almost identical to the labeled amount. This result confirms highly accurate formulation with minimal deviation.
As a newly tested product, additional lab reports over time will provide further insight into long-term batch consistency. However, this initial result demonstrates strong precision and reliability.
Frequently Asked Questions
Yes, the lab test shows a measured dosage of 2.52 mg per tablet, which is extremely close to the labeled 2.5 mg.
Yes, a deviation of around 0.8% is considered very precise, especially for low-dose tablet formulations.
The available report was conducted by Janoshik, an independent laboratory.
Currently, only one lab test is available. Additional reports may provide further insight into batch consistency over time.
